

# ABL Diagnostics announces the payment of its first dividend for the 2024 financial year

*ABL Diagnostics announces its first dividend for 2024 since the 2022 merger that led activity in the field of genotyping diagnostics of infectious diseases*

WOIPPY, MOSELLE, FRANCE, June 25, 2025 /EINPresswire.com/ -- The Shareholders' Meeting of



First dividend for 2024 financial year since the 2022 merger that led ABL Diagnostics' activity in the field of genotyping diagnostics of infectious diseases"

*Dr Chalom B. Sayada*

ABL Diagnostics, held on Tuesday, June 24, 2025 at 11 a.m., approved all the resolutions submitted to its vote, and in particular the payment of a [dividend](#) of €0.05 per share for the 2024 financial year, i.e. a total distribution of €805,732.80 (based on the total number of shares forming the share capital, i.e. 16,114,656 shares, which will, if necessary, be adjusted downwards to take into account the shares deprived of dividend rights (treasury shares) on the ex-dividend date.

The amount of the unit dividend to be paid to these shares

will be allocated to the item "Carry forward again".

The ex-dividend date will be June 27, 2025 and the dividend will be paid on July 1, 2025, exclusively in cash.

The voting results for each resolution will be available on the Company's website no later than July 9, 2025.

\*\*\*\*\*

## About ABL Diagnostics

ABL Diagnostics specializes in proprietary molecular biology assays and end-to-end solutions for precise molecular detection and genotyping:

- UltraGene – real-time PCR-based molecular detection.
- DeepChek® – DNA sequencing for genotyping.

## Expanding Portfolio for Microbiology

Our growing portfolio covers:

- HIV diagnostics – Drug resistance assays, including a Whole Genome Kit.

- SARS-CoV-2, Tuberculosis, Hepatitis B & C – Advanced genotyping and drug resistance analysis
- Microbiome & Taxonomy – 16s/18s RNA-based analysis.
- Other viral & bacterial targets – Comprehensive molecular assays.

#### Syndromic & Digital Solutions

- Syndromic Real-Time PCR assays (known-how and IP acquired in 2025).
- Nadis® – EMR system used in 200+ hospitals in France for HIV & Hepatitis infected patients management.

ABL DIAGNOSTICS is listed on the Euronext Compartment B market of NYSE EURONEXT - ISIN code: FR001400AHX6

Dr Sayada

ABL Diagnostics SA

+33 7 83 64 68 50

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/825558315>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.